You are here

Merck

Merck discard jumps straight to the top of the chart of the most expensive drugs in the US at $1M-plus

Endpoints

Mon, 03/8/21 - 09:24 pm

Eiger Pharmaceuticals

Biotech Pandion's secret to moving a $65M Merck offer to a $1.9B done deal in a year? Just keep saying no

Fierce Biotech

Fri, 03/5/21 - 10:45 am

Merck enters multiple agreements for supply of Covid-19 medicines and vaccines

Pharmaceutical Business Review

Wed, 03/3/21 - 10:50 am

drug manufacturing

Biden invokes federal law to broker Merck, J&J Covid vaccine manufacturing alliance

MedCity News

Wed, 03/3/21 - 12:07 am

drug manufacturing

Merck follows Bristol's suit, pulling Keytruda's SCLC nod. Is the FDA's accelerated approval reckoning finally here?

Fierce Pharma

Tue, 03/2/21 - 12:14 pm

small cell lung cancer

Bristol-Myers Squibb

Merck, Johnson & Johnson to strike 'wartime' COVID-19 vaccine manufacturing deal: WaPo

Fierce Pharma

Tue, 03/2/21 - 10:58 am

drug manufacturing

Artiva, fresh from Merck pact, raises $120M for NK therapy R&D

Fierce Biotech

Mon, 03/1/21 - 10:39 am

natural killer cell therapy

FDA accepts gefapixant for review in cough, positioning Merck to get head start on Bayer and Bellus

Fierce Biotech

Mon, 03/1/21 - 10:38 am

Merck's OncoImmune COVID-19 Therapeutic Stuck at Starting Gate Pending Further Data

BioSpace

Sun, 02/28/21 - 10:16 pm

Merck inks $1.9B Pandion takeover to square up against Amgen, Lilly and Roche

Fierce Biotech

Thu, 02/25/21 - 10:44 am

immune modulators

Overcoming chemotherapy resistance in leukemia with a diarrhea drug from Merck

Fierce Biotech

Thu, 02/25/21 - 09:57 am

Libtayo scores second OK in two weeks, this time for front-line NSCLC. Can it take on Keytruda?

Endpoints

Mon, 02/22/21 - 11:51 pm

non-small cell lung cancer

Did Merck Make a Mistake With a Key FDA Filing?

Motley Fool

Sun, 02/21/21 - 11:54 pm

triple negative breast cancer

Moving up the lines, AstraZeneca stakes another PhIII win for Lynparza as adjuvant breast cancer therapy

Endpoints

Wed, 02/17/21 - 11:21 am

clinical trials

BRCA-mutant breast cancer

Merck's Keytruda Plus Eisai's Lenvima Could Open New Standard of Care in Renal Cancer

BioSpace

Tue, 02/16/21 - 11:12 am

renal cell carcinoma

Another Keytruda combo tops standard of care in advanced kidney cancer, posing new test for Bristol's I/O med

Endpoints

Sun, 02/14/21 - 09:23 pm

advanced kidney cancer

Amgen loses appeal in patent suit against Sanofi/Regeneron’s Praluent. It’s a bummer for Bristol Myers Squibb and Merck, too

Endpoints

Fri, 02/12/21 - 10:48 am

How Merck, a Vaccine Titan, Lost the Covid Race

NY Times, NY

Thu, 02/11/21 - 10:42 pm

FDA panel admonishes Merck with a gentle — and rare — slapdown for rushing its pitch on an accelerated OK for adjuvant Keytruda in TNBC

Endpoints

Wed, 02/10/21 - 12:00 am

Merck’s Kenneth Frazier, biopharma’s irreplaceable voice, to step down as CEO

Stat

Thu, 02/4/21 - 10:54 am

Pages